- Home
- MAIA vs CELU Comparison
MAIA vs CELU Comparison
Compare MAIA & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- CELU
- Stock Information
- Founded
- MAIA 2018
- CELU 2016
- Country
- MAIA United States
- CELU United States
- Employees
- MAIA N/A
- CELU N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- MAIA Health Care
- CELU Health Care
- Exchange
- MAIA Nasdaq
- CELU Nasdaq
- Market Cap
- MAIA 56.7M
- CELU 56.9M
- IPO Year
- MAIA 2022
- CELU N/A
- Fundamental
- Price
- MAIA $1.32
- CELU $2.00
- Analyst Decision
- MAIA
- CELU Strong Buy
- Analyst Count
- MAIA 0
- CELU 1
- Target Price
- MAIA N/A
- CELU $6.00
- AVG Volume (30 Days)
- MAIA 594.6K
- CELU 224.7K
- Earning Date
- MAIA 11-11-2025
- CELU 12-05-2025
- Dividend Yield
- MAIA N/A
- CELU N/A
- EPS Growth
- MAIA N/A
- CELU N/A
- EPS
- MAIA N/A
- CELU N/A
- Revenue
- MAIA N/A
- CELU $44,590,000.00
- Revenue This Year
- MAIA N/A
- CELU N/A
- Revenue Next Year
- MAIA N/A
- CELU $76.00
- P/E Ratio
- MAIA N/A
- CELU N/A
- Revenue Growth
- MAIA N/A
- CELU 4.45
- 52 Week Low
- MAIA $1.27
- CELU $1.00
- 52 Week High
- MAIA $3.48
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- MAIA 34.23
- CELU 41.41
- Support Level
- MAIA $1.65
- CELU $1.93
- Resistance Level
- MAIA $1.97
- CELU $2.35
- Average True Range (ATR)
- MAIA 0.12
- CELU 0.16
- MACD
- MAIA -0.05
- CELU 0.03
- Stochastic Oscillator
- MAIA 4.45
- CELU 18.85
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.